Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 531

1.

Dietary Cellulose Supplementation Modulates the Immune Response in a Murine Endotoxemia Model.

Di Caro V, Cummings JL, Alcamo AM, Piganelli JD, Clark RSB, Morowitz MJ, Aneja RK.

Shock. 2018 May 8. doi: 10.1097/SHK.0000000000001180. [Epub ahead of print]

PMID:
30080745
2.

Lack of Benefit on Brain Edema, Blood-Brain Barrier Permeability or Cognitive Outcome in Global, Inducible HMGB1 Knockout Mice despite Tissue Sparing after Experimental Traumatic Brain Injury.

Aneja RK, Alcamo A, Cummings JL, Vagni VA, Janesko-Feldman KL, Wang Q, Dixon CE, Billiar T, Kochanek PM.

J Neurotrauma. 2018 Jul 26. doi: 10.1089/neu.2018.5664. [Epub ahead of print]

PMID:
30045665
3.

Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study.

Torosyan N, Sethanandha C, Grill JD, Dilley ML, Lee J, Cummings JL, Ossinalde C, Silverman DH.

Exp Gerontol. 2018 Jul 10;111:118-121. doi: 10.1016/j.exger.2018.07.009. [Epub ahead of print]

PMID:
30006299
4.

Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume.

Caldwell JZK, Berg JL, Shan G, Cummings JL, Banks SJ; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;64(1):79-89. doi: 10.3233/JAD-180028.

5.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.

PMID:
29719179
6.

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R.

Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25.

7.

Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study.

Berg JL, Durant J, Léger GC, Cummings JL, Nasreddine Z, Miller JB.

J Alzheimers Dis. 2018;62(1):93-97. doi: 10.3233/JAD-170896.

8.

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.

Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL.

JAMA. 2018 Jan 9;319(2):130-142. doi: 10.1001/jama.2017.20373.

9.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13. Review.

PMID:
29237794
10.

Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease.

Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J, Murphy M, Riordan H, Scheinin M, Soininen H, Rouru J.

Alzheimers Dement (N Y). 2016 Dec 8;3(1):1-9. doi: 10.1016/j.trci.2016.11.004. eCollection 2017 Jan.

11.

Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume.

Caldwell JZK, Berg JL, Cummings JL, Banks SJ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2017 Sep 12;9(1):72. doi: 10.1186/s13195-017-0300-8.

12.

Contrasting roles of the ABCG2 Q141K variant in prostate cancer.

Sobek KM, Cummings JL, Bacich DJ, O'Keefe DS.

Exp Cell Res. 2017 May 1;354(1):40-47. doi: 10.1016/j.yexcr.2017.03.020. Epub 2017 Mar 11.

13.

Validation Study of the Korean Version of the Brief Clinical Form of the Neuropsychiatric Inventory.

Kim HJ, Choi KH, Kim SH, Cummings JL, Yang DW.

Dement Geriatr Cogn Dis Extra. 2016 Jun 3;6(2):214-21. doi: 10.1159/000445828. eCollection 2016 May-Aug.

14.

Concordance of the Montreal cognitive assessment with standard neuropsychological measures.

Vogel SJ, Banks SJ, Cummings JL, Miller JB.

Alzheimers Dement (Amst). 2015 Jun 28;1(3):289-94. doi: 10.1016/j.dadm.2015.05.002. eCollection 2015 Sep.

15.

Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply.

Cummings JL, Siffert J.

JAMA. 2016 Mar 15;315(11):1166-7. doi: 10.1001/jama.2015.18289. No abstract available. Erratum in: JAMA. 2016 Apr 19;315(15):1661.

PMID:
26978215
16.

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.

Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, Pontecorvo M, Devous M, Tang A, Bena J.

Alzheimers Res Ther. 2016 Jan 29;8:4. doi: 10.1186/s13195-016-0173-2.

17.

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.

Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gandara JE, Agronin M, Davis CS, Nguyen U, Shin P, Tariot PN, Siffert J.

JAMA. 2015 Sep 22-29;314(12):1242-54. doi: 10.1001/jama.2015.10214.

PMID:
26393847
18.

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials.

Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL.

Alzheimers Res Ther. 2015 Jun 25;7(1):39. doi: 10.1186/s13195-015-0122-5. eCollection 2015.

19.

Incidence of dementia and subtypes: A cohort study in four regions in China.

Yuan J, Zhang Z, Wen H, Hong X, Hong Z, Qu Q, Tang M, Wu J, Xu Q, Li H, Cummings JL.

Alzheimers Dement. 2016 Mar;12(3):262-71. doi: 10.1016/j.jalz.2015.02.011. Epub 2015 Jun 15.

PMID:
26086181
20.

Values of the Minimal Clinically Important Difference for the Neuropsychiatric Inventory Questionnaire in Individuals with Dementia.

Mao HF, Kuo CA, Huang WN, Cummings JL, Hwang TJ.

J Am Geriatr Soc. 2015 Jul;63(7):1448-52. doi: 10.1111/jgs.13473. Epub 2015 Jun 5.

PMID:
26046666
21.

A practical algorithm for managing Alzheimer's disease: what, when, and why?

Cummings JL, Isaacson RS, Schmitt FA, Velting DM.

Ann Clin Transl Neurol. 2015 Mar;2(3):307-23. doi: 10.1002/acn3.166. Epub 2015 Jan 23. Review.

22.

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch.

Molinuevo JL, Frölich L, Grossberg GT, Galvin JE, Cummings JL, Krahnke T, Strohmaier C.

Alzheimers Res Ther. 2015 Mar 8;7(1):9. doi: 10.1186/s13195-014-0088-8. eCollection 2015.

23.

Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.

Ringman JM, Liang LJ, Zhou Y, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus DS, Farlow M, Ghetti B, McDade E, Masters CL, Mayeux RP, Rossor M, Salloway S, Schofield PR, Cummings JL, Buckles V, Bateman R, Morris JC; Dominantly Inherited Alzheimer Network.

Brain. 2015 Apr;138(Pt 4):1036-45. doi: 10.1093/brain/awv004. Epub 2015 Feb 15. Erratum in: Brain. 2015 Dec;138(Pt 12):e401.

24.

Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease.

Alva G, Cummings JL, Galvin JE, Meng X, Velting DM.

Int J Clin Pract. 2015 May;69(5):518-30. doi: 10.1111/ijcp.12621. Epub 2015 Feb 16.

PMID:
25684069
25.

Alzheimer's disease.

Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL.

Nat Rev Dis Primers. 2015 Oct 15;1:15056. doi: 10.1038/nrdp.2015.56. Review.

PMID:
27188934
26.

Overcoming obstacles to repurposing for neurodegenerative disease.

Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, Fillit HM.

Ann Clin Transl Neurol. 2014 Jul;1(7):512-8. doi: 10.1002/acn3.76. Epub 2014 Jun 24.

27.

Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

Cummings JL, Morstorf T, Zhong K.

Alzheimers Res Ther. 2014 Jul 3;6(4):37. doi: 10.1186/alzrt269. eCollection 2014.

28.

Sensitivity to change of composite and frequency scores of the neuropsychiatric inventory in mild cognitive impairment.

Cummings JL, Tribanek M, Hoerr R.

Int Psychogeriatr. 2014 Nov;26(11):1871-4. doi: 10.1017/S1041610214001185. Epub 2014 Jul 3.

PMID:
24990088
29.

Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes.

Miller JB, Banks SJ, Léger GC, Cummings JL.

Transl Neurodegener. 2014 Jun 5;3:12. doi: 10.1186/2047-9158-3-12. eCollection 2014. Review.

30.

Novel nuclear localization of fatty acid synthase correlates with prostate cancer aggressiveness.

Madigan AA, Rycyna KJ, Parwani AV, Datiri YJ, Basudan AM, Sobek KM, Cummings JL, Basse PH, Bacich DJ, O'Keefe DS.

Am J Pathol. 2014 Aug;184(8):2156-62. doi: 10.1016/j.ajpath.2014.04.012. Epub 2014 Jun 5.

31.

Higher working memory predicts slower functional decline in autopsy-confirmed Alzheimer's disease.

Pillai JA, Bonner-Jackson A, Walker E, Mourany L, Cummings JL.

Dement Geriatr Cogn Disord. 2014;38(3-4):224-33. doi: 10.1159/000362715. Epub 2014 Jun 4.

32.

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL.

Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. Erratum in: Lancet Neurol. 2014 Aug;13(8):757.

PMID:
24849862
33.

Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan™).

Cummings JL, Fine MJ, Grachev ID, Jarecke CR, Johnson MK, Kuo PH, Schaecher KL, Oberdorf JA, Rezak M, Riley DE, Truong D.

Am J Manag Care. 2014 Mar;20(5 Suppl):S97-109.

34.

Neuropathologic correlates of trial-related instruments for Alzheimer's disease.

Cummings JL, Ringman J, Vinters HV.

Am J Neurodegener Dis. 2014 Mar 28;3(1):45-9. eCollection 2014.

35.

The "Alzheimer's type" profile of semantic clustering in amnestic mild cognitive impairment.

McLaughlin PM, Wright MJ, Larocca M, Nguyen PT, Teng E, Apostolova LG, Ringman JM, Zhou Y, Cummings JL, Woo E.

J Int Neuropsychol Soc. 2014 Apr;20(4):402-12. doi: 10.1017/S135561771400006X. Epub 2014 Feb 13.

36.

Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.

Cummings JL, Zhong K.

Expert Rev Clin Pharmacol. 2014 Mar;7(2):161-5. doi: 10.1586/17512433.2014.884923. Epub 2014 Feb 6.

PMID:
24502586
37.

Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease.

Apostolova LG, Di LJ, Duffy EL, Brook J, Elashoff D, Tseng CH, Fairbanks L, Cummings JL.

Dement Geriatr Cogn Disord. 2014;37(5-6):315-26. doi: 10.1159/000351009. Epub 2014 Jan 25.

38.

Discovering new treatments for Alzheimer's disease by repurposing approved medications.

Appleby BS, Cummings JL.

Curr Top Med Chem. 2013;13(18):2306-27. Review.

PMID:
24059463
39.

Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.

Salmon DP, Ferris SH, Thomas RG, Sano M, Cummings JL, Sperling RA, Petersen RC, Aisen PS.

Neuropsychology. 2013 Jul;27(4):391-401. doi: 10.1037/a0032707.

40.

Alzheimer's disease biomarkers in animal models: closing the translational gap.

Sabbagh JJ, Kinney JW, Cummings JL.

Am J Neurodegener Dis. 2013 Jun 21;2(2):108-20. Print 2013.

41.

Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study.

Apostolova LG, Babakchanian S, Hwang KS, Green AE, Zlatev D, Chou YY, DeCarli C, Jack CR Jr, Petersen RC, Aisen PS, Cummings JL, Toga AW, Thompson PM.

Alzheimer Dis Assoc Disord. 2013 Apr-Jun;27(2):174-81. doi: 10.1097/WAD.0b013e3182677b3d.

42.

Medical Clinics of North America. Early diagnosis and intervention in predementia Alzheimer's disease. Preface.

Molinuevo JL, Cummings JL, Dubois B, Scheltens P.

Med Clin North Am. 2013 May;97(3):xiii-xv. doi: 10.1016/j.mcna.2013.01.003. Epub 2013 Feb 22. No abstract available.

PMID:
23642584
43.

Clinical trials in predementia stages of Alzheimer disease.

Pillai JA, Cummings JL.

Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22. Review.

PMID:
23642580
44.

International Work Group criteria for the diagnosis of Alzheimer disease.

Cummings JL, Dubois B, Molinuevo JL, Scheltens P.

Med Clin North Am. 2013 May;97(3):363-8. doi: 10.1016/j.mcna.2013.01.001. Epub 2013 Feb 16.

PMID:
23642575
45.

Alzheimer's disease biomarkers: correspondence between human studies and animal models.

Sabbagh JJ, Kinney JW, Cummings JL.

Neurobiol Dis. 2013 Aug;56:116-30. doi: 10.1016/j.nbd.2013.04.010. Epub 2013 Apr 28. Review.

PMID:
23631871
46.

Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts.

Trzepacz PT, Saykin A, Yu P, Bhamditipati P, Sun J, Dennehy EB, Willis B, Cummings JL; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2013 Jul;21(7):607-22. doi: 10.1016/j.jagp.2012.10.027. Epub 2013 Apr 18.

47.

Toward a more precise, clinically--informed pathophysiology of pathological laughing and crying.

Lauterbach EC, Cummings JL, Kuppuswamy PS.

Neurosci Biobehav Rev. 2013 Sep;37(8):1893-916. doi: 10.1016/j.neubiorev.2013.03.002. Epub 2013 Mar 18. Review.

PMID:
23518269
48.

Alzheimer's disease drug development: translational neuroscience strategies.

Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K.

CNS Spectr. 2013 Jun;18(3):128-38. doi: 10.1017/S1092852913000023. Epub 2013 Mar 11. Review.

PMID:
23472637
49.

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.

Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P.

CNS Neurosci Ther. 2013 May;19(5):294-301. doi: 10.1111/cns.12076. Epub 2013 Mar 6. Review.

PMID:
23462265
50.

The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments.

Kim HJ, Kang SJ, Kim C, Kim GH, Jeon S, Lee JM, Oh SJ, Kim JS, Choe YS, Lee KH, Noh Y, Cho H, Yoon CW, Chin J, Cummings JL, Lee JH, Na DL, Seo SW.

Neurobiol Aging. 2013 Jul;34(7):1913-20. doi: 10.1016/j.neurobiolaging.2013.01.002. Epub 2013 Feb 13.

PMID:
23414669

Supplemental Content

Loading ...
Support Center